
    
      This study is a phase IIb, 4 arm study with three month active dosing period. Three of the
      four treatment groups will be randomized to either Androxal or placebo in a double-blind
      fashion, and the fourth treatment group will receive open-label Testim. The doses of Androxal
      in the blinded portion of the study will be 12.5 mg and 25 mg, in capsule form.
    
  